Home
    • Plans Blog Contact
    Relief Therapeutics Holding SA logo

    Relief Therapeutics Holding SA

    RLFTY
    Last price US$0.422
    Market cap US$5.3b
    12M price change N/A
    Loading the 12-month Mave Thesis and 1-month news signal

    Industry and sector peers, plus broader research alternatives

    View comparison
    Halozyme Therapeutics IncHALO Industry peer Corcept Therapeutics IncorporatedCORT Industry peer Exelixis IncEXEL Industry peer Zoetis IncZTS Sector peer
    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    Relief Therapeutics Holding SA Overview

    Industry: Biotechnology

    Sector: Healthcare

    Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis. The company also develops RLF-TD011, a hypochlorous acid topical sprayable solution to treat wound colonization, reduce local inflammation, alleviate symptoms, and hasten wound healing in epidermolysis bullosa. In addition, it develops OLPRUVA, a sodium phenylbutyrate for the treatment of various inborn errors of metabolism, urea cycle disorders, and maple syrup urine disease; APR-OD32, which is in phase 1 for the treatment of patients with phenylketonuria. Relief Therapeutics Holding AG was founded in 2013 and is based in Geneva, Switzerland. Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The c Read More

    Mavefund brings filings, fundamentals, valuation, price history and news for Relief Therapeutics Holding SA into one research view. The sections below show what strengthens or weakens the research case.

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Dec 16, 2024

    Quarterly result summary

    Exhibit 99.1 Ad hoc announcement pursuant to Art. 53 LR Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Company to Maintain SIX Swiss Exchange Listing, U.S. ADR Program, and U.S. OTCQB Quotation GENEVA (DEC. 13, 2024) –...

    What changed

    • Review the SEC source filing for the full reported results and management commentary.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR DECEMBER, 2024 Dec 16, 2024 SEC filing FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR NOVEMBER, 2024 Nov 12, 2024 Earnings release PRESS RELEASE DATED NOVEMBER 11, 2024 Nov 12, 2024 SEC filing FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR NOVEMBER, 2024 Nov 05, 2024 Earnings release PRESS RELEASE DATED NOVEMBER 4, 2024 Nov 05, 2024 SEC filing FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR OCTOBER, 2024 Oct 28, 2024 Earnings release PRESS RELEASE DATED OCTOBER 25, 2024 Oct 28, 2024 SEC filing FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR OCTOBER, 2024 Oct 22, 2024 Earnings release PRESS RELEASE DATED OCTOBER 21, 2024 Oct 22, 2024 SEC filing FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER FOR OCTOBER, 2024 Oct 09, 2024 Earnings release PRESS RELEASE DATED OCTOBER 8, 2024 Oct 09, 2024

    Prediction-grade evidence

    Recent News

    Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

    No qualified company news in the last 14 days

    No recent article passed both the company-relevance and source-reliability checks. Research continues to use the other available filings, fundamentals, market data, and valuation inputs.

    Earnings Per Share

    Score 0.00/5
    Relief Therapeutics Holding SA earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Return on Equity

    Score 3.78/5
    Relief Therapeutics Holding SA stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Relief Thera... RLFTY US$5.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Net Margin

    Score 4.14/5
    Relief Therapeutics Holding SA commands a high score, propelled by its net margin consistently outpacing the sector median value and exhibiting continuous growth in recent six years; noteworthy counterparts in the sector, boasting similarly high scores, include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    Relief Thera... RLFTY US$5.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Share Buyback

    In Biotechnology industry , Halozyme Therapeutics Inc , Corcept Therapeutics Incorporated , Exelixis Inc are companies with high ratings.

    Leverage

    Score 4.83/5
    Relief Therapeutics Holding SA attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    Relief Thera... RLFTY US$5.3b
    Zoetis Inc ZTS US$31.9b
    IQVIA Holdin... IQV US$34.8b
    Agilent Tech... A US$37.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    Verified SEC statements load when this section enters view.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    Relief Therapeutics Holding SA logo

    Relief Therapeutics Holding SA

    US$0.422

    US$5.3b

    0.00%

    N/A